Galderma has presented new data at EADV 2026 showing that patients with moderate-to-severe atopic dermatitis maintained sustained improvements on Nemluvio (nemolizumab) for up to three years of treatment.

The long-term findings extend the evidence base for nemolizumab, an IL-31 receptor antagonist that blocks the signaling of interleukin-31, a cytokine central to the itch and inflammation that drive atopic dermatitis. The new dataset answers a question clinicians ask of every biologic in this indication: do the efficacy signals seen in pivotal trials hold up over years of real-world continued dosing?

For dermatologists managing moderate-to-severe disease, durability matters as much as induction-phase response. Atopic dermatitis is chronic and relapsing, and treatments that lose efficacy over time — or whose safety profile degrades with cumulative exposure — force cycling between agents. Three years of sustained improvement positions nemolizumab alongside the longer-term datasets that have accumulated for dupilumab and the JAK inhibitor class, though head-to-head comparisons were not part of this presentation.

Nemolizumab has built its profile around pruritus. Itching, not erythema alone, is the symptom patients rank as most burdensome, and therapies that specifically target IL-31 signaling offer a mechanistically distinct approach to that endpoint. Galderma's latest data indicate the improvements observed earlier in the treatment course — in skin clearance and itch — persist through the three-year mark in the continuation population studied.

The announcement comes from Galderma's EADV 2026 presentation, where the company assembled its long-term extension results for the Nemluvio development program in moderate-to-severe atopic dermatitis. Full details on cohort size, baseline characteristics, and the specific efficacy endpoints reported — including the proportions of patients maintaining validated response measures — accompany the congress materials.

Nemluvio's regulatory trajectory has already established it as a treatment option in atopic dermatitis, and Galderma has been broadening the franchise into other IL-31-mediated conditions, with prurigo nodularis among the indications where the agent has gained approval. The three-year atopic dermatitis data add a durability data point that payers and formulary committees weigh heavily when positioning a biologic against established competitors.

Longer exposure windows also sharpen the safety picture. Cumulative data across multiple years give clinicians a more reliable read on tolerability than the 16-to-52-week windows typical of pivotal trials, and sustained efficacy without emerging safety concerns is the combination that supports continued use in routine practice.

Full results from the EADV 2026 presentation are expected to inform how dermatologists counsel patients starting nemolizumab on what to expect from multi-year therapy, and peer-reviewed publication of the complete dataset will determine how the three-year findings shape treatment guidelines for moderate-to-severe atopic dermatitis.